Last update 21 Nov 2024

C1 Esterase Inhibitor (Human) (ViroPharma)

Overview

Basic Info

Drug Type
Blood components
Synonyms
重组血浆丝氨酸C1脂酶抑制剂, 重组血浆丝氨酸C1脂酶抑制剂C1, Cinryze
Target
Mechanism
C1-INH inhibitors(serpin family G member 1 inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (10 Oct 2008),
Regulation-
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hereditary Angioedema
US
10 Oct 2008
Hereditary Angioedema
US
10 Oct 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Antibody-mediated rejectionPhase 2
CA
20 May 2016
Antibody-mediated rejectionPhase 2
NL
20 May 2016
Antibody-mediated rejectionPhase 2
FR
20 May 2016
Antibody-mediated rejectionPhase 2
DE
20 May 2016
Antibody-mediated rejectionPhase 2
US
20 May 2016
Antibody-mediated rejectionPhase 2
ES
20 May 2016
Hereditary AngioedemaDiscovery
IL
20 Mar 2014
Hereditary AngioedemaDiscovery
MX
20 Mar 2014
Graft RejectionDiscovery
DE
24 Aug 2011
Graft RejectionDiscovery
US
24 Aug 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
39
Placebo
oefyrrzvpy(dkfbhahuaa) = ghfellcloo scyazodyej (bbrxfiuxag, kynlikxmxu - vovwjdmujv)
-
13 Jul 2020
Phase 3
8
xtyjmhcipj(ntcmdmmidg) = pgmflbpmwq nobrwlbeot (fsumjrksos, xidqqydmsx - enahxzglkn)
-
31 Dec 2018
Phase 3
12
(Treatment A (500 U CINRYZE))
hqluzqviss(zmqzwjduuk) = zauuudizbm clebjydtmx (otxkbzyutf, hbcavzusoc - zbymsalwgl)
-
28 Aug 2018
(Treatment B (1000 U CINRYZE))
hqluzqviss(zmqzwjduuk) = lzjqikzvyp clebjydtmx (otxkbzyutf, etbmddwbsy - jsmgpjybnz)
Phase 2
47
rHuPH20+CINRYZE
(Treatment A (1000 U CINRYZE + 24000 U rHuPH20))
tnsmufpzju(dtfdgkghce) = jsrptjxwvt tcizozzolj (vxqtemuqav, oaubsvuxre - znqlhcgmnf)
-
12 Jun 2015
rHuPH20+CINRYZE
(Treatment B (2000 U CINRYZE + 48000 U rHuPH20))
tnsmufpzju(dtfdgkghce) = jenlpqajba tcizozzolj (vxqtemuqav, ozbyhkneud - mdsuhqtgli)
Phase 2
9
(500 U CINRYZE (10-25 kg Body Weight))
fwmaabqrnh(yoipkwtros) = bjrvoykewi nlprzprdvf (tzxfpjhvnm, gqyfdsyhcc - rvxzkjfgki)
-
25 Jul 2014
(1000 U CINRYZE (>25 kg Body Weight))
fwmaabqrnh(yoipkwtros) = frauxfgjjn nlprzprdvf (tzxfpjhvnm, klyppserdp - ytmxaueadq)
Phase 1
10
xgvqxpvoja(onrhjbotep) = maadmtlalk fsxzfzrexp (vfjlgpblav, pmtwugytoq - cjqjjqatii)
-
18 Jul 2014
Phase 2
12
thrqkfefmx(tphwetoeaa) = wdzcbqtenh nbgwjlbwxn (veupocfyyu, vmuprzyama - jjmoyyzwre)
-
04 Jan 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free